Market: NMS |
Currency: USD
Address: 149 Fifth Avenue
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.
📈 Protagenic Therapeutics, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
-
-
Upside/Downside from Analyst Target:
-
-
Broker Call:
-
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
50-100%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
-
-
Upcoming Earnings Date:
-
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for Protagenic Therapeutics, Inc.
| Date | Reported EPS |
|---|
| 2022-04-07 | -2.79 |
| 2021-11-15 | -2.8 |
📰 Related News & Research
-
Protagenic Therapeutics, Inc. (PTIX) 10-Q Quarterly Report for December 31, 2025 – Financials, Filings, and Nasdaq Listing
March 9, 2026
Protagenic Therapeutics, Inc. Q3 2025 Financial Report: Inve...
-
Protagenic Therapeutics, Inc. Files Form 8-K Current Report with SEC – Company Details, Addresses, and Trading Symbols (Feb. 3, 2026)
March 3, 2026
Protagenic Therapeutics, Inc. Files Form 8-K: Key Details fo...
🔍 View more Reports
